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Plasmodium falciparum malaria developed in an Af-
rican-born traveler who returned to Canada after visiting 
Nigeria. While there, she took artesunate prophylactically. 
Isolates had an elevated 50% inhibitory concentration to ar-
temisinin, artesunate, and artemether, compared with that 
of other African isolates. Inappropriate use of artemisinin 
derivatives can reduce P. falciparum susceptibility.
A
rtemisinin derivatives were recently approved by the 
Food and Drug Administration for the treatment of 
Plasmodium falciparum malaria in North America and are 
available through the US Centers for Disease Control and 
Prevention and through Health Canada (1–3). Artemisinin-
based combination therapy (ACT) remains the most ef-
fective therapy for P. falciparum malaria throughout the 
world, with the possible exception of the Thailand–Cam-
bodia border (4). Because of the large numbers in the To-
ronto area of returning travelers and recent immigrants who 
have returned to countries of origin and visited friends and 
relatives, the Public Health Laboratory (Toronto) identiﬁ  es 
≈200 positive malaria smears annually; most P. falciparum 
isolates have come from sub-Saharan Africa. Evidence has 
indicated that such travelers tend not to seek medical ad-
vice before travel and are therefore at high risk of acquiring 
malaria (5).
The Patient
A 38-year-old Nigerian-born woman, who lived in the 
Toronto area (and has a good ability to recount her experi-
ences), returned to Lagos, Nigeria, for a visit in January 
2009. She did not seek pretravel advice. On arrival in La-
gos, the woman purchased artesunate locally and began 
taking two 50-mg tablets weekly for the 4 weeks of her 
visit. Immediately on her return to Toronto, the patient ex-
perienced myalgia, nausea with vomiting, and chills, ≈7 
days after she had taken her last dose of oral artesunate. 
She sought treatment at the emergency department of a 
community hospital. Physical examination showed that her 
temperature was 39.1°C and that she was dehydrated. Lab-
oratory tests showed the following: leukocyte count 3,700 
cells/μL, thrombocyte count 72 × 103 cells/μL, hemoglobin 
level 12.7 g/dL. Her chest radiograph showed that her lungs 
were clear. An examination of peripheral blood by thick 
and thin blood ﬁ  lms showed a 0.7% parasitemia with P. 
falciparum. Her condition was treated with 1,250 mg of 
oral meﬂ  oquine as a single dose. She was treated as an out-
patient, and she reported that symptoms promptly resolved 
over the next 48 hours without side effects. 
A blood specimen was placed into culture in the Public 
Health Laboratory (Toronto), and the P. falciparum isolate 
was tested for drug susceptibility (6). The 50% inhibitory 
concentration (IC50) was the following for certain antimi-
crobial agents (tested in triplicate): chloroquine 170.5 ± 7.8 
nmol/L, meﬂ  oquine 16.6 ± 0.7 nmol/L, artemisinin 20.1 ± 
0.6 nmol/L, artesunate 6.2 ± 1.4 nmol/L, dihydroartemisi-
nin 1.8 ± 0.9 nmol/L, and artemether 21.4 ± 5.3 nmol/L. 
For this P. falciparum isolate, IC50 was signiﬁ  cantly higher 
for artemisinin, artesunate, and artemether than for other 
representative P. falciparum isolates imported from Africa 
(Figure). Because of the short half-life of artesunate, the 
weekly doses of the oral drug may have led to develop-
ment of a resistant strain when the patient was in Nige-
ria. Artesunate-containing drugs therefore should not be 
used for prophylaxis or single drug therapy. The purchased 
artesunate may also have been counterfeit and may have 
contained lower levels of active drug. Although these data 
suggest that this isolate has reduced susceptibility to ar-
temisinin derivatives, the correlation between in vitro sus-
ceptibility and treatment outcomes does not appear to be 
consistent (4).
Previous studies have reported that resistance to ar-
temisinin is mediated by an increase in gene copy number, 
mutations within the efﬂ  ux pump of the P. falciparum mul-
tidrug resistance 1 (pfmdr1) gene, or mutations in the calci-
um transporter pfATPase6 (7,8). When we examined each 
gene, using a combination of real-time PCR and DNA se-
quencing, we found that pfmdr1 copy number was elevated 
in this isolate relative to that of the susceptible control strain 
3D7. We also observed nonsynonymous mutations in both 
pfmdr1 (Y184F) and pfATPase6 (A623E, S769N), whereas 
other implicated residues remained in the wild-type form 
(9) (Table). Similar molecular analysis of other representa-
tive imported African clinical isolates demonstrated vari-
able mutations for pfmdr1 and pfATPase6 and copy num-
ber in relation to IC50 values for key drugs (Table). A trend, 
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albeit weak, was observed in which increased pfmdr1 copy 
number was correlated with an elevated IC50 to meﬂ  oquine 
(r = 0.52) and artemisinin (r = 0.42). The presence of an 
asparagine (N) at position 86 of Pfmdr1, when coupled to 
an elevated pfmdr1 copy number, appeared to correlate 
well with reduced susceptibility to artemisinin (Table). 
Chavchich et al. recently demonstrated that increased pf-
mdr1 copy number occurred in a laboratory strain placed 
under drug selection pressure with artemisinin derivatives 
(11). However, Imwong et al. have indicated that genetic 
polymorphisms and copy number in pfmdr1 do not predict 
treatment outcome with ACT (10).
Findings in the published literature vary in terms of 
use of artemisinin derivatives for in vitro drug susceptibil-
ity testing. Jambou et al. reported treatment failures with 
ACT in Cambodia, French Guiana, and Senegal (8). These 
authors used artemether for testing and showed IC50 val-
ues of ≈30 nmol/L in their “resistant” isolates from Sen-
egal. Noedl et al. described treatment failures with ACT 
in Cambodia, for which IC50 values to dihydroartemisinin 
were ≈10 nmol/L (12). Dondorp et al. showed IC50 values 
of 4–6 nmol/L to dihydroartemisinin and 6–8 nmol/L to 
artesunate in a region of Cambodia and Thailand where 
ACT treatment failures have occurred (4). Systematic mo-
lecular surveillance and standardized drug-testing methods 
with clinical isolates are required to establish the molecular 
correlates of reduced susceptibility to antimalarial drugs. 
In this regard, efforts are ongoing under the auspices of the 
Worldwide Antimalarial Research Network (13).
Conclusions
The patient’s infection responded to meﬂ  oquine when 
she was back in Canada, possibly because of the high oral 
dose of meﬂ  oquine. Current guidelines from the US Cen-
ters for Disease Control and Prevention recommend quinine 
sulfate plus doxycycline, tetracycline, or clindamycin; or 
atovaquone-proguanil (Malarone; GlaxoSmithKline, Mis-
sissauga, Ontario, Canada) as ﬁ  rst- and second-line treat-
ment for uncomplicated P. falciparum malaria. Reduced 
susceptibility to artesunate is more likely to occur when it 
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Table. Results of sequencing single-nucleotide polymorphisms of Plasmodium falciparum isolate*
Strain
Pfmdr1 PfATPase pfmdr1 
copy no. 
CQ IC50,
nmol/L
MQ IC50,
nmol/L
ART IC50,
nmol/L 86 184 1034 1042 1246  623 769
3D7 N Y S N D A S 1.00 6.1 2.1 6.1
W2 Y Y S N D A S 0.97 252 3.2 7.3
Cameroon Y F S N D E N 1.85 163 7.7 8.07
Congo Y F S N D E N 1.51 355 10.7 10.9
Kenya Y F S N D E N 1.75 282 11.7 10.1
Liberia N F S N D E N 1.65 109 16.2 16.5
Nigeria C  Y F S N D E N 1.06 222 8.7 8.1
Nigeria A  N F S N D E N 1.52 171 16.6 20.1
Nigeria B  Y F S N D E N 1.09 188 5.6 10.0
Ghana N F S N D E N 0.96 24.0 11.6 14.2
Tanzania Y F S N Y E N 1.88 381 7.8 16.6
Angola Y F S N D E N 0.81 258 4.5 7.3
*At Pfmdr1 and PfATPase6 residues previously implicated in artemisinin resistance and gene copy number of pfmdr1 by quantitative real-time PCR in 
relation to mean IC50 (n = 3) data for key drugs (7,8,10). pfmdr1, P. falciparum multidrug resistance 1; CQ, chloroquine; MQ, mefloquine; ART, 
artemisinin; IC50., 50% minimum inhibitory concentration; N, asparagine; Y, tyrosine; S, serine; D, aspartic acid; A, alanine; E, glutamic acid; 3D7, 
chloroquine-sensitive laboratory strain; W2, chloroquine-resistant laboratory strain; Nigeria A, clinical isolate described in this report.†
Figure. In vitro drug susceptibility of representative 
patient isolates from returning travelers who 
visited friends and relatives in Africa. The 
mean 50% inhibitory concentrations (IC50) of 
chloroquine, meﬂ  oquine, artemisinin, artesunate, 
dihydroartemisinin, and artemether are plotted in 
nmol/L for each isolate, performed in triplicate 
(error bars indicate SD; n = 3). Nigeria A denotes 
the patient described in this report. The black 
horizontal line represents the median value.is associated with inappropriate use of artemisinin deriva-
tives than because of circulating artemisinin-resistant P. 
falciparum in sub-Saharan Africa.
In an effort to achieve consensus that artesunate oral 
monotherapies should not be marketed, the World Health 
Organization convened the international pharmaceutical 
sector in April 2006. At that time, 15 companies agreed to 
cease manufacturing artesunate monotherapies. However, 
oral artesunate montherapies may still be purchased over the 
counter in malaria-endemic countries, as this report shows. 
Thus, strains of P. falciparum malaria are currently at risk of 
developing reduced susceptibility to artesunate derivatives.  
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